multiple myeloma

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

multiple myeloma
Apr 23, 2024, 23:38 | Drugs
Vincent Rajkumar: All the drug approvals for relapsed multiple myeloma in 20 years
Tina Crosbie, Hematology Pharmacist at The Ottawa Hospital and at Extend Pharmacy, shared a post…
Apr 23, 2024, 14:08 | Blog
Elizabeth Franklin: International Myeloma Foundation Gala
Elizabeth Franklin shared on LinkedIn: "Approximately 35,000 people are diagnosed with multiple myeloma in the…
Apr 23, 2024, 12:45 | Insight
Myeloma Paper of the Day, April 23rd, suggested by Robert Orlowski
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Apr 21, 2024, 16:39 | Insight
Myeloma Paper of the Day, April 21st, suggested by Robert Orlowski
Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X: "Myeloma…
Apr 20, 2024, 17:31 | Blog
The U.S. FDA recently approved two CAR T-cell therapies for earlier treatment of adults with multiple myeloma - The Leukemia and Lymphoma Society
The Leukemia and Lymphoma Society shared a post on LinkedIn: "PROGRESS! The U.S. FDA recently approved…
Apr 20, 2024, 16:47 | Insight
Myeloma Paper of the Day, April 20th, suggested by Robert Orlowski
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Apr 20, 2024, 05:56 | Insight
Myeloma Paper of the Day suggested by Robert Orlowski, April 18th
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Apr 17, 2024, 18:24 | Insight
Myeloma paper of the Day suggested by Robert Orlowski, April 17th
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Apr 17, 2024, 17:09 | Blog
Foorquan Hashmi: Our collective commitment is embodied in the belief that 'Cancer doesn't take a day off: neither do we'
Foorquan Hashmi, Assistant Managing Editor at OncoDaily, shared a post by OncoDaily, on LinkedIn: "That's amazing news!…
Apr 17, 2024, 10:31 | Insight
Myeloma Paper of the Day - Robert Orlowski
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Apr 16, 2024, 01:57 | Insight
Cancer Network's top 5 articles of the week
Quoting Cancer Network on X/Twitter: "View our top 5 articles of the week: FDA Grants…
Apr 15, 2024, 11:06 | Blog
Rahul Banerjee: This is fascinating, even if rare
Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington…
Apr 14, 2024, 12:56 | Insight
Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs
Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared…
Apr 13, 2024, 03:43 | Blog
FDA ODAC voted 12-0. Historic victory in multiple myeloma
On April 12, 2024, FDA ODAC voted 12-0 in favor of using minimal residual disease…
Apr 9, 2024, 17:56 | Insight
Myeloma Paper of the Day - Robert Z. Orlowski
Robert Z. Orlowski, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma…
Apr 4, 2024, 12:14 | Blog
Sarah Belcher: Looking forward to presenting our research team's findings on adherence to oral anticancer medications in patients with Multiple Myeloma at ASCO 2024
Sarah Belcher, Assistant Professor in Health and Community Systems at the University of Pittsburgh School of…
Mar 27, 2024, 04:49 | Insight
Sarju Ganatra: Cardiotoxity of CAR T-cell Therapy in Multiple Myeloma
Sarju Ganatra, Vice Chair at Lahey Hospital Department of Medicine Research, shared a post on…
Mar 20, 2024, 22:47 | Blog
In each podcast episode, fellow myeloma patients share their experiences and perspectives - Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation, made the following post on X: “In each podcast episode, fellow…
Mar 20, 2024, 16:53 | Insight
Vincent Rajkumar: ODAC votes 11-0 to recommend approval of Cilta-Cel in patients with relapsed/refractory multiple myeloma in earlier stages
Vincent Rajkumar, Editor in Chief of Blood Cancer Journal, shared on X/Twitter: "Breaking: ODAC votes…
Mar 19, 2024, 21:14 | Blog
Carl Ola Landgren: We had full program in Coral Gables for Multiple Myeloma Awarness Month
Carl Ola Landgren, Chief of Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive…
Mar 17, 2024, 13:43 | Insight
Samer Al Hadidi: How to counsel patients about Cilta Cel
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Mar 15, 2024, 15:46 | Opinion
Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies
Nizar Jacques Bahlis, Associate Professor of Medicine at the University of Calgary, posted on X:…
Mar 13, 2024, 22:31 | Blog
Emily Morris-McCarthy: Inspired by the impactful patient journey during Myeloma Awareness Month
Emily Morris-McCarthy, General Manager, Head of US Oncology at Sanofi, shared on their LinkedIn: ''Every…
Mar 7, 2024, 12:52 | Blog
Selwyn Vickers: Thank you to the The Wall Street Journal Health Forum for including me in a panel discussion on the future of cancer care with Kathryn Giusti
Selwyn Vickers, President and CEO of Memorial Sloan Kettering Cancer Center, recently shared a post…
Feb 29, 2024, 19:11 | Insight
Robert Z. Orlowski: Myeloma Paper of the Day
Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X/Twitter:…
Feb 25, 2024, 15:31 | Opinion
Aaron Goodman: Until a trial demonstrates melflufen is superior to melphalan I see no reason to use it
Aaron Goodman shared a post on X: "Chemo is bad and toxic! Attach a peptide…
Feb 23, 2024, 14:39 | Insight
Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Feb 19, 2024, 15:48 | Career
Damian Green joins Sylvester Cancer in March and will help lead translational research
Prominent oncologist and researcher Damian Green, M.D., will join Sylvester Comprehensive Cancer Center at the…
Feb 14, 2024, 13:50 | Drugs
Robert Z. Orlowski: Myeloma Paper of the Day
Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, posted on X/Twitter:…
Feb 12, 2024, 06:26 | Insight
Natalia Baran: This work by Natthakan Thongon, Feiyang Ma and colleagues, unravels a new approach of overcoming metabolic reprogramming in multiple myeloma
Natalia Baran, Research Assistant Professor at MD Anderson Cancer Center, shared on LinkedIn: "Just published in…
Feb 6, 2024, 16:42 | Blog
Triplet Therapy Offers New Treatment Option for Patients with Relapsed or Refractory Multiple Myeloma - ASCO
American Society of Clinical Oncology (ASCO) shared a post on their LinkedIn page: "Latest from…
Jan 27, 2024, 08:16 | Insight
Stephen Nimer: Another important publication from Sylvester’s multiple myeloma team that will be practice changing!
Stephen Nimer, Director at Sylvester Comprehensive Cancer Center, recently shared a post by Sylvester Comprehensive…
Jan 19, 2024, 13:42 | Insight
Zhen Su: Another Sea Change of oncology care led by cancer immunotherapy
Zhen Su, Physician Scientist, Entrepreneur and CEO at Marengo Therapeutics, shared a post on LinkedIn:…
Jan 8, 2024, 15:21 | Career
Lawrence Boise: Looking for motivated postdocs to study factors that control mitochondrial priming and cell survival in multiple myeloma
Quoting Lawrence Boise, R. Randall Rollins Chair in Oncology at Emory University School of Medicine,…
Dec 17, 2023, 17:14 | Insight
Ajay Major: Critically important multiple myeloma study from ASH23
Quoting Ajay Major, Assistant Professor at the University of Colorado School of Medicine and Founder…
Dec 14, 2023, 15:41 | Insight
Samer Al Hadidi: Will use of CAR-T earlier be better?
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Dec 9, 2023, 16:37 | Opinion
Aaron Goodman: My prediction (American Society of Hematology 2023)
Aaron Goodman shared a post on X/Twitter: "My prediction is the plenary session at American…
Nov 28, 2023, 23:17 | Insight
Manni Mohyuddin: Current trials must have observation/surveillance as control arm
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Nov 17, 2023, 17:31 | Blog
Natalia Neparidze: This event is open to all community members and provides education about myeloma
Natalia Neparidze, Hematology and Multiple Myeloma specialist at Yale University, shared on X/Twitter: "Please join…
Oct 26, 2023, 09:18 | Blog
Vincent Rajkumar: After 20 years since inception, we got the final completion from CIRB today
Vincent Rajkumar, Editor in Chief of Blood Cancer Journal, posted on Twitter: "I’m really proud…
Oct 9, 2023, 18:51 | Opinion
Urvi Shah: If you are a patient with myeloma or any plasma cell disorder please consider filling out this survey.
Urvi Shah, Attending Physician in Myeloma Service at Memorial Sloan Kettering Cancer Centre, shared on X/Twitter:…
Oct 3, 2023, 17:43 | Drugs,Insight
Rafael Fonseca: The clinical development curse against venetoclax for t(11;14) multiple myeloma.
Rafael Fonseca, the Chief Innovation Officer at Mayo Clinic, Arizona, recently tweeted on X/Twitter: ''The…
Sep 5, 2023, 17:52 | Insight
Linda B. Baughn: I hope WGS for MM will be a standard clinical assay in the future.
Linda B. Baughn, Co-director of Cytogenetics Laboratory at Mayo Clinic, recently tweeted: "I hope WGS…
Sep 3, 2023, 05:14 | Insight
Dickran (Diko) Kazandjian: MRD in BM precedes CR in peripheral blood necessitating new definitions of MRD negativity independently of serum markers.
Dickran (Diko) Kazandjian, a Professor of Medicine at the Sylvester Comprehensive Cancer Center and a…
Aug 22, 2023, 18:16 | Opinion
Aaron Goodman: The way we treat multiple myeloma will bankrupt the system and further enrich pharma.
According to Aaron Goodman on Twitter/X: "The way we treat multiple myeloma will bankrupt the…
Aug 14, 2023, 17:11 | Drugs
Joshua Richter: Another myeloma approval today! Elrexfio
In a post by Joshua Richter, Associate Professor of Medicine at Mount Sinai, it says:…
Aug 14, 2023, 16:41 | Drugs
Chris Boshoff: Science Will Win Against Multiple Myeloma
In a post on LinkedIn by Chris Boshoff, Chief Oncology Research and Development Officer and…
Aug 13, 2023, 10:01 | Blog,Drugs
Rahul Banerjee: How do we standardize the standard of care for bortezomib (Velcade) in multiple myeloma?
Rahul Banarjee, Assistant Professor in the Division of Medical Oncology at the University of Washington,…
May 27, 2023, 16:54 | Opinion
Is There An 'Optimal' Carfilzomib Dose For Relapsed Or Refractory MM?- Blood Cancer Today
A new study suggests there is an “optimal” dose of carfilzomib for patients with relapsed…
12
All: 149 Posts: 101 - 200